1. . ICSD-2 – International Classification of Sleep Disorders: Diagnostic and Coding Manual, 2nd ed. American Academy of Sleep Medicine; 2005.
2. , , , et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001;57:2029–33.
3. , , , et al. A long-term prognosis of narcolepsy: 10–20 year follow-up study of patients diagnosed with narcolepsy during 1958–1969. Jpn J Clin Psychiatr 1980;9:485–93.
4. , , . The clinical and polygraphic development of narcolepsy. In , , eds. Sleep/Wake Disorders: Natural History, Epidemiology and Long-Term Evolution. New York: Raven Press; 1983: pp. 171–85.
5. , , , et al. Fragmented sleep, daytime somnolence and age in narcolepsy. Clin Electroencephalogr 1989;20:49–54.
6. , , . Comparison in symptoms between aged and younger patients with narcolepsy. Psychiatry Clin Neurosci 2001;55:241–2.
7. , , , et al. The implications of gender and age at onset of first symptoms in narcoleptic patients in Germany: results from retrospective evaluation of hospital records. Somnologie 2002;6:13–18.
8. , , , et al. How age influences the expression of narcolepsy. J Psychosom Res 2005;59:399–405.
9. , , , et al. Presentation of narcolepsy after 40. Neurology 1998;50:459–65.
10. , , , et al. Epidemiology of narcolepsy. Sleep 1994;17:S7–S12.
11. , , , et al. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology 2004;62:46–50.
12. . In , ed. Narcolepsy and Hypersomnia. Basel, New York: Karger; 1980.
13. . Sleep and its Disorders. Philadelphia: W.B. Saunders Company; 1985.
14. , , , et al. Night sleep does not predict day sleep in narcolepsy. Electroenceph Clin Neurophysiol 1994;91:67–70.
15. , , , et al. Komorbidität bei Narkolepsiepatienten. Dtsch Med Wochenschr 2002;127:1942–46.
16. , , . Comorbidity in narcolepsy. In , , , eds. Narcolepsy and Hypersomnia. New York: Informa Healthcare USA; 2007: pp. 485–96.
17. , . Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behaviour disorder. Ann Neurol 1992;32:3–10.
18. , . Motor dyscontrol in sleep of narcoleptic patients (a lifelong development?). J Sleep Res 1993;2:143–8.
19. , , , et al. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med 2005;6:253–8.
20. , , , et al. REM sleep characteristics in narcolepsy and REM sleep behavior disorder. Sleep 2007;30:844–9.
21. , , et al. Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull 2006;70:386–90.
22. , , et al. Combination of “idiopathic” REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005;128:126–37.
23. , , et al. Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder. Brain 2007;130:442–9.
24. , , et al. Localization of orexins and their receptors in the rat olfactory system: possible modulation of olfactory perception by a neuropeptide synthesized centrally or locally. Brain Res 2003;960:48–61.
25. , , , et al. Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res 2007;16:333–9.
26. , , , et al. Modafinil: a double-blind multicenter study. Sleep 1994;17(Suppl.):107–12.
27. , , , et al. Randomized, double-blind placebo-controlled crossover trial of modafinil in the treatment of excessive sleepiness in narcolepsy. Neurology 1997;49:444–51.
28. . Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88–97.
29. , , , et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22:757–65.
30. . Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166–75.
31. , , , et al. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol 2004;27:74–9.
32. . A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42–9.
33. . Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415–21.
34. , . Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;2:939–46.
35. . Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119–23.
36. , . All-day performance variations in normal and narcoleptic subjects. Sleep 1986;9:200–4.
37. , . Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 1993;16:444–56.
38. , . The effects of regularly scheduled naps on sleep attacks and excessive daytime sleepiness associated with narcolepsy. Nursing Res 1993;42:111–7.
39. , , . A comparison of three different sleep schedules for reducing sleepiness in narcolepsy. Sleep 2001;24:385–91.
40. , , . Melatonin for treatment of REM sleep behaviour disorder in neurological disorders: results in 14 patients. Sleep Med 2003;4:281–4.